A Bicester School Sixth Form student "rediscovered her love of learning" earlier this year following a summer internship at ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

Johnson is co-founder of Boston-based Affinia Therapeutics and former CEO of UK biopharma Adrestia Therapeutics Kesmalea's SELFTAC® platform is designed to solve the 'size problem' of large, bifunctio ...

The severe asthma market is fueled by the rising prevalence of the condition, particularly in urban areas, alongside the emergence of innovative therapies ...

MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year ...

Vertex (VERX) delivered earnings and revenue surprises of 14.29% and 2.96%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

News sites don't have a "genuine choice" about whether to block Google AI crawlers from scraping their content, a publisher ...